Evidence map›Paper›PMID 35768939›Full record

Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2022

Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.

Corey C Ford, Jeffrey A Cohen, Andrew D Goodman, John W Lindsey, Robert P Lisak, Christopher Luzzio, Amy Pruitt, John Rose, Horea Rus, Jerry S Wolinsky and 4 more

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 2 countries.

Corey C FordDepartment of Neurology, University of New Mexico Health Sciences Center, The University of New Mexico, Albuquerque, NM, USA.
Jeffrey A CohenMellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0001-9245-9772
Andrew D GoodmanDepartment of Neurology, University of Rochester, Rochester, NY, USA.
John W LindseyDepartment of Neurology, University of Texas Health Science Center at Houston (UTHouston), Houston, TX, USA.ORCID 0000-0001-6856-0811
Robert P LisakDepartment of Neurology and Department of Biochemistry, Microbiology and Immunology, School of Medicine, Wayne State University, Detroit, MI, USA.
Christopher LuzzioDepartments of Neurology and Engineering, University of Wisconsin-Madison, Madison, WI, USA.
Amy PruittDepartment of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA, USA.
John RoseImaging and Neuroscience Center, School of Medicine, The University of Utah, Salt Lake City, UT, USA.
Horea RusDepartment of Neurology, School of Medicine, University of Maryland, Baltimore, MD, USA.
Jerry S WolinskyDepartment of Neurology, University of Texas Health Science Center at Houston (UTHouston), Houston, TX, USA.ORCID 0000-0002-8197-2762
Shaul E KadoshInnovative Research and Development, Teva Pharmaceuticals, Netanya, Israel.
Emily Bernstein-HanlonGlobal Clinical Programming, Teva Pharmaceuticals, Netanya, Israel.
Yafit StarkGlobal Clinical Development, Teva Pharmaceuticals, Netanya, Israel.
Jessica K AlexanderGlobal Medical Affairs, Teva Pharmaceuticals, West Chester, PA, USA/Jazz Pharmaceuticals, Palo Alto, CA, USA.
Teva Pharmaceuticals (Israel) · ILThe University of Texas Health Science Center at Houston · USCleveland Clinic · USJazz Pharmaceuticals (United States) · USUniversity of Maryland, Baltimore · USUniversity of New Mexico · USUniversity of Pennsylvania · USUniversity of Rochester · USUniversity of Utah · USUniversity of Wisconsin–Madison · USWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlatiramer acetate (GA) is US-approved for relapsing multiple sclerosis.

objectivesTo describe GA long-term clinical profile. To compare effectiveness of early start (ES) versus delayed start (DS; up to 3 years) with GA.

methodsPhase 3 trial participants entered a randomized placebo-controlled period then an open-label extension (OLE) with GA.

resultsOverall, 208 out of 251 (82.9%) randomized participants entered the OLE; 24 out of 101 (23.8%, ES) and 28 out of 107 (26.2%, DS) participants completed the OLE. Median GA treatment was 9.8 (0.1-26.3) years. Annualized change in Expanded Disability Status Scale (EDSS) score was lower with ES versus DS (

conclusionGA long-term treatment maintained clinical benefit with a similar safety profile to phase 3 results; a key limitation was that only 25% of participants completed the OLE. Early initiation of GA had sustained benefits versus delayed treatment.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingFollow-Up StudiesGlatiramer AcetateHumansImmunosuppressive AgentsRecurrenceTime-to-TreatmentGlatiramer AcetateImmunosuppressive AgentsClinical trialdisease-modifying therapiesglatiramer acetatemultiple sclerosisquality of liferelapsing/remitting

Identifiers

PMID35768939
PMCPMC9442630
OpenAlexW4283718337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.